Heat shock proteins 90-alpha (HSP90

Diagnostic Heat shock proteins 90-alpha (HSP90

Target products collectionGo to Neurodegenerative diseases diagnostics products collection >>


Product information

Catalog No. Description US $ Price (per mg)
GMP-h-HSP90-Ag01 Recombinant human HSP90AA1/HSP90 3090
GMP-h-HSP90-Ab01 Anti-human HSP90AA1/HSP90 1953
GMP-h-HSP90-Ab02 Anti-human HSP90AA1/HSP90 1953
GMP-h-HSP90-Ab03 Anti-human HSP90AA1/HSP90 1953
GMP-h-HSP90-Ab04 Anti-human HSP90AA1/HSP90 1953

Size: 1mg | 10mg | 100mg



Product Description

Cat No. of Products GMP-h-HSP90-Ag01
Product Name Recombinant human HSP90AA1/HSP90
Target/Biomarker Heat shock proteins 90-alpha (HSP90(HSP90)
Alias of Target/Biomarker EL52, HEL-S-65p, HSP86, HSP89A, HSP90A, HSP90N, HSPC1, HSPCA, HSPCAL1, HSPCAL4, HSPN, Hsp103, Hsp89, Hsp90, LAP-2, LAP2
Expression platform mammalian
Isotypes Recombinant Antigen
Bioactivity validation Heat shock proteins 90-alpha (HSP90 (HSP90) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in HSP90 level test of Cancer (renal cancer, liver cancer and breast cancer) and related syndrome evaluation.
Products description Recombinant human HSP90AA1/HSP90 was expressed in mammalian expression system and is expressed with 6 HIS tag at the C-terminus.
Purity Purity: ≥95% (SDS-PAGE)
Application Standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT.
Formulation Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products GMP-h-HSP90-Ab01, GMP-h-HSP90-Ab02, GMP-h-HSP90-Ab03, GMP-h-HSP90-Ab04
Product Name Anti-human HSP90AA1/HSP90
Target/Biomarker Heat shock proteins 90-alpha (HSP90(HSP90)
Alias of Target/Biomarker EL52, HEL-S-65p, HSP86, HSP89A, HSP90A, HSP90N, HSPC1, HSPCA, HSPCAL1, HSPCAL4, HSPN, Hsp103, Hsp89, Hsp90, LAP-2, LAP2
Expression platform CHO
Isotypes Mouse IgG
Bioactivity validation Human Heat shock proteins 90-alpha (HSP90 (HSP90) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Heat shock proteins 90-alpha (HSP90 (HSP90) antibodies in HSP90 level test of Cancer (renal cancer, liver cancer and breast cancer) and related syndrome evaluation.
Tag mFc
Products description Anti-human HSP90AA1/HSP90 is a monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Purity Purity: ≥95% (SDS-PAGE)
Application ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.
Formulation Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Validation Data


    Click to get more Data / Case study about the product.



    Target/Biomarker information

    The Hsp90 family of heat shock proteins represents one of the most abundantly expressed and highly conserved families of cellular chaperones whose expression can be upregulated under conditions of cellular stress, and includes cytoplasmic (Hsp90-alpha/beta), ER (grp94), and mitochondrial (TRAP1) localized members. Structurally, Hsp90 is characterized by an N-terminal ATP-binding domain, a medial substrate-binding domain, and a C-terminal dimerization motif. Hsp90 dimers function in cooperation with cochaperones (e.g. Hsp40, Hsp70, Hop, p23) to stabilize a multitude of client protein substrates, including steroid hormone receptors, protein kinases, and transcription factors. The essential binding and hydrolysis of ATP by Hsp90 is inhibited by ansamycin drugs (e.g. geldanamycin, 17-AAG) which occupy the N-terminal Hsp90 nucleotide-binding pocket. Many Hsp90 client proteins such as erbB2/Her-2, c-raf, bcr-abl, p53, and hTERT, are members of well characterized oncogenic pathways, making Hsp90 inhibitors useful anticancer agents.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.

    Comments


    No comments yet.

    Leave a comment